Generex Oral-lyn Shows Promising Results in Treating Type 1 Diabetes

Strategic Insights -

A long-term clinical trial by Generex Biotechnology Corporation has demonstrated the efficacy of its oral insulin spray, Generex Oral-lyn, in improving metabolic control in adolescents and young adults with Type 1 diabetes mellitus. The study showed that replacing one daily subcutaneous injection of regular insulin with Generex Oral-lyn during the day improved parameters of metabolic control, including daily glucose profiles and fructosamine. Notably, glycosylated hemoglobin (HbA1c), the criterion standard to evaluate metabolic control in diabetes, showed a significant improvement when compared to standard therapy.

Key Takeaways:

  • Generex Oral-lyn demonstrated a significant improvement in glycosylated hemoglobin (HbA1c) levels compared to standard therapy, indicating better metabolic control in patients with Type 1 diabetes mellitus.
  • The study showed that replacing one daily subcutaneous injection of regular insulin with Generex Oral-lyn during the day improved daily glucose profiles and fructosamine levels.
  • The oral insulin spray was associated with 100% compliance among patients, indicating that it may be a more patient-friendly alternative to traditional insulin injections.
  • The results of the study justify further investigation into the use of Generex Oral-lyn as a replacement for traditional insulin therapy in larger populations of patients with Type 1 diabetes.
  • The study highlights the importance of maintaining good metabolic control in diabetes to prevent complications and improve quality of life.
  • Dr. Guevara-Aguirre's results demonstrate the potential of Generex Oral-lyn to improve compliance and outcomes in patients with Type 1 diabetes.

Statistics:

  • 24 adolescents and 5 young adult patients with Type 1 diabetes mellitus participated in the clinical trial.
  • 100% of patients using Generex Oral-lyn showed significant improvement in HbA1c levels compared to standard therapy.
  • The oral insulin spray improved daily glucose profiles and fructosamine levels in patients.
  • The study aimed to investigate the potential of Generex Oral-lyn as a replacement for traditional insulin therapy in patients maintained on once-daily glargine insulin therapy.

Sources:

  • Generex Biotechnology Corporation (GNBT)
  • "Prevalence and Correlates of Depressed Mood Among Youth with Diabetes" (Pediatrics, April 2006)
  • World Disease Weekly via NewsRx.com